Literature DB >> 22827853

Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects.

C Tang, T Godfrey, R Stawell, M Nikpour.   

Abstract

Due to multiple beneficial effects, including control of disease activity, reduction in cardiovascular events and improved survival, hydroxychloroquine is now recommended long-term for all patients with systemic lupus erythematosus. However, patients must be made aware of the possible risk of retinal toxicity and have eye examinations to monitor for this complication. As hydroxychloroquine becomes more widely used in systemic lupus erythematosus, physicians must also be aware of rare but serious adverse effects, including neuromyotoxicity and cardiotoxicity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22827853     DOI: 10.1111/j.1445-5994.2012.02886.x

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  29 in total

1.  The vascular phenotype of children with systemic lupus erythematosus.

Authors:  Catherine Quinlan; Jameela Kari; Clarissa Pilkington; John Deanfield; Rukshana Shroff; Stephen D Marks; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2015-05-23       Impact factor: 3.714

Review 2.  Why are kids with lupus at an increased risk of cardiovascular disease?

Authors:  Catherine Quinlan; Stephen D Marks; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2015-09-23       Impact factor: 3.714

Review 3.  Towards new avenues in the management of lupus glomerulonephritis.

Authors:  C C Mok
Journal:  Nat Rev Rheumatol       Date:  2016-01-05       Impact factor: 20.543

4.  Area-Level Predictors of Medication Nonadherence Among US Medicaid Beneficiaries With Lupus: A Multilevel Study.

Authors:  Candace H Feldman; Karen H Costenbader; Daniel H Solomon; S V Subramanian; Ichiro Kawachi
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-07       Impact factor: 4.794

5.  Unbiased modifier screen reveals that signal strength determines the regulatory role murine TLR9 plays in autoantibody production.

Authors:  Robyn E Mills; Viola C Lam; Allison Tan; Nicole Cresalia; Nir Oksenberg; Julie Zikherman; Mark Anderson; Arthur Weiss; Michelle L Hermiston
Journal:  J Immunol       Date:  2015-03-13       Impact factor: 5.422

6.  Breast milk concentration of hydroxychloroquine in Chinese lactating women with connective tissue diseases.

Authors:  Wenxiu Peng; Rongji Liu; Lejia Zhang; Qiang Fu; Dan Mei; Xiaoli Du
Journal:  Eur J Clin Pharmacol       Date:  2019-08-02       Impact factor: 2.953

Review 7.  Hydroxychloroquine retinopathy.

Authors:  I H Yusuf; S Sharma; R Luqmani; S M Downes
Journal:  Eye (Lond)       Date:  2017-03-10       Impact factor: 3.775

8.  Arthritis and use of hydroxychloroquine associated with a decreased risk of macrophage activation syndrome among adult patients hospitalized with systemic lupus erythematosus.

Authors:  E M Cohen; K D'Silva; D Kreps; M B Son; K H Costenbader
Journal:  Lupus       Date:  2018-02-16       Impact factor: 2.911

Review 9.  Systemic lupus erythematosus and ocular involvement: an overview.

Authors:  Rosanna Dammacco
Journal:  Clin Exp Med       Date:  2017-12-14       Impact factor: 3.984

10.  Distribution of hydroxychloroquine in lymphoid tissue in a rabbit model for HIV infection.

Authors:  Iliana González-Hernández; Lucinda Aguirre-Cruz; Julio Sotelo; Raquel López-Arellano; Adriana Morales-Hipólito; Helgi Jung-Cook
Journal:  Antimicrob Agents Chemother       Date:  2013-10-21       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.